Brynovin is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 23, 2040. Details of Brynovin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11944621 | Oral gliptin compositions and method for preparation thereof |
Oct, 2040
(15 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Brynovin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Brynovin's family patents as well as insights into ongoing legal events on those patents.
Brynovin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Brynovin's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 23, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Brynovin Generics:
There are no approved generic versions for Brynovin as of now.
About Brynovin
Brynovin is a drug owned by Azurity Pharmaceuticals Inc. Brynovin uses Sitagliptin Hydrochloride as an active ingredient. Brynovin was launched by Azurity in 2025.
Approval Date:
Brynovin was approved by FDA for market use on 16 January, 2025.
Active Ingredient:
Brynovin uses Sitagliptin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Sitagliptin Hydrochloride ingredient
Dosage:
Brynovin is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 25MG BASE/ML | SOLUTION | Prescription | ORAL |